What is the main business of Nutriceptics Poland?

The main business activity of Nutriceptics Poland focuses on manufacture of food supplements.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on February 24, 2021.

Where is the headquarters located?

The headquarters is located at: ul. Glinki 144B, 85-861 Bydgoszcz.

What is the share capital?

The share capital of the company is PLN 50,000 (approx. $13,506).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

How much revenue was generated?

The company reported a revenue of USD 9,546 in 2025, which is a decrease of 95.0% compared to 2024.

Is the company profitable?

No, in 2025 the company was not profitable, reporting a net loss of USD 3,888. For comparison, in 2024 the loss was USD 6,002, meaning the company reduced its loss by 35.4%.

What is the main operating cost?

The largest operating cost category falls under other operating costs. This category amounted to USD 9,822 in 2025, representing 84% of all operating expenses.

Nutriceptics Polandsp. z o.o.

Manufacture of food supplements

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2021-02-24

Share capital

50,000.00 PLN

Activity description

Nutriceptics Poland is a privately held company founded in Bydgoszcz in 2021, developing brands and ventures in preventive and metabolic health. It builds them using data and biomarkers, and substantiates claims with evidence.

Registered address

ul. Glinki 144B, 85-861 Bydgoszcz, Poland

Website

nutriceptics.com

Electronic delivery address

AE:PL-41578-71584-VFCSH-23

Financials

Revenue history (in k)

Filing timeliness

2 of 5 financial statements were filed late (the longest delay 59 days for 2021).

202517/02/2026
202411/02/2025
202310/06/2024
202224/07/2023
202112/09/2022

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 9.55kMedianUSD 344.81kAverageUSD 7.75m

Net profit

This companyUSD -3.89kMedianUSD 4.84kAverageUSD 649.54k

Operating costs

This companyUSD 11.67kMedianUSD 396.72kAverageUSD 6.83m

Assets

This companyUSD 1.13kMedianUSD 356.06kAverageUSD 7.50m

Industry

Authorized Representatives

Arkadiusz Paweł Szmytkowski – Management Board Member

Jakub Jan Szatkowski – President of the Management Board

Manner of representation

If the management board is a multi-member management board, joint action of two members of the management board or of a member of the management board jointly with a commercial proxy is required to represent the company, including for making declarations of will on behalf of the company.

Supervisory board

Lucyna Ewa Weroniczak – Supervisory Board Member

Mikołaj Weroniczak – Supervisory Board Member

Wojciech Szatkowski – Supervisory Board Member

Ownership

Owner	Shares	Share value	Stake
Jakub Jan Szatkowskiage 40	250	$3,376.55	25%
Arkadiusz Paweł Szmytkowskiage 39	250	$3,376.55	25%
Mikołaj Weroniczakage 19	500	$6,753.11	50%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2021-04-01.

PKO Bank Polski
75 1020 1475 0000 8102 0308 7202

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Psiapsisp. z o.o.	$89,376.33	psiapsi.pl
Cannabis PolandS.A.	$55,015.30	cannabispolandsa.com
Symbio PolskaS.A.	$9,938.92	symbio.pl

Change history

Date	Event
2026-08-31	Business suspended
2026-06-16	Address change (Ul. Lawendowa 1 Ab, 86-031, Osielsko → Ul. Glinki 144b, 85-861, Bydgoszcz)
2026-06-16	Share capital increase (5,000.00 PLN → 50,000.00 PLN)
2026-06-16	Name change (Lunidore → Nutriceptics Poland)
2026-05-26	Business resumed

FAQ

Last updated: 2026-10-03